Sleeping Pills Global Market Report 2026

Sleeping pills, also known as sedative-hypnotics, are medications used to assist individuals in falling asleep or maintaining sleep. They are frequently prescribed for the short-term management of insomnia or other sleep-related disorders. Sleeping pills work by depressing the central nervous system, which induces drowsiness and supports restful sleep.

The main types of sleeping pills include prescription sleeping pills and over-the-counter (OTC) sleeping pills. Sleeping pills are medications or supplements intended to help improve the ability to fall asleep, remain asleep, or enhance overall sleep quality. These include various product types such as benzodiazepines and non-benzodiazepines and are used to manage sleep disorders including insomnia, sleep apnea, restless leg syndrome, narcolepsy, and sleepwalking. Demand for sleeping pills differs across consumer groups based on factors such as age, gender, and health status. These products are distributed through several channels, including retail pharmacies, online pharmacies, hospitals and clinics, and health and wellness stores.

Tariffs have impacted the sleeping pills market by increasing costs for imported active pharmaceutical ingredients (APIs) and herbal supplements. Segments such as non-benzodiazepine prescription drugs and herbal sleep aids are most affected, with regions like Asia-Pacific, including China and India, facing higher import duties. This has resulted in elevated production costs and supply chain adjustments. On the positive side, tariffs have encouraged domestic manufacturing and local sourcing of raw materials, fostering innovation and reducing dependency on imports.

The sleeping pills market research report is one of a series of new reports from The Business Research Company that provides sleeping pills market statistics, including sleeping pills industry global market size, regional shares, competitors with a sleeping pills market share, detailed sleeping pills market segments, market trends and opportunities, and any further data you may need to thrive in the sleeping pills industry. This sleeping pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sleeping pills market size has grown strongly in recent years. It will grow from $85.87 billion in 2025 to $93.03 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to limited availability of sleep disorder treatments, growing insomnia prevalence, dominance of prescription sleeping pills, traditional pharmacy distribution channels, low awareness about sleep hygiene.

The sleeping pills market size is expected to see strong growth in the next few years. It will grow to $126.55 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to development of novel non-benzodiazepine drugs, rising adoption of melatonin and herbal supplements, increasing online pharmacy penetration, personalized sleep treatment programs, expanding geriatric and adult consumer base. Major trends in the forecast period include rising prevalence of sleep disorders globally, increased adoption of over-the-counter sleep aids, growing focus on personalized sleep therapy, expansion of online pharmacies and e-commerce channels, rising awareness about natural and herbal sleep supplements.

The growing prevalence of mental illness is anticipated to drive the expansion of the sleeping pills market in the coming years. Mental illness encompasses a broad spectrum of mental health conditions that influence an individual's mood, thoughts, behavior, and overall functioning. The rise in mental illness prevalence is largely attributed to increasing levels of chronic stress, as prolonged stress can disrupt normal brain activity and trigger or exacerbate mental health disorders. Sleeping pills support the management of mental illness by improving sleep quality, which is crucial for emotional balance and cognitive stability. They help alleviate symptoms such as anxiety and depression by promoting restorative sleep and enhancing overall mental well-being and daily performance. For example, in 2025, according to the National Alliance on Mental Illness and NextStep Solutions Behavioral Health, US-based health agencies reported that the prevalence of serious mental illness (SMI) was approximately 5.44% in 2023 and remained similar in 2024 at around 5.6% of adults, indicating relative stability within this severe category. Therefore, the increasing prevalence of mental illness is contributing to the growth of the sleeping pills market.

Major companies operating in the sleeping pills market are concentrating on developing advanced solutions, such as novel drug formulations, to improve sleep quality while minimizing dependency risks and reducing adverse side effects. Novel drug formulations involve the creation of new medication compositions aimed at enhancing therapeutic effectiveness, improving absorption, lowering side effects, and offering more targeted and patient-friendly treatment options. For instance, in October 2024, Neurovalens, a UK-based medical device company, launched Modius Sleep, a Food and Drug Administration (FDA)-cleared, physician-prescribed medical device designed to treat chronic insomnia in adults aged 22 and older. The device utilizes low-level electrical vestibular nerve stimulation to target the hypothalamus and brainstem, which regulate sleep and circadian rhythms. It is worn on the head for 30 minutes each evening, typically 1-2 hours before bedtime, with adjustable intensity to ensure user comfort. Modius Sleep is portable, easy to use, and can be worn during activities such as reading or watching television.

In October 2023, Apnimed, a US-based pharmaceutical company, entered into a partnership with Shionogi & Co. Ltd. This collaboration aims to develop innovative pharmacological therapies for obstructive sleep apnea and other sleep disorders, with a focus on novel oral treatment options. Shionogi & Co. Ltd. is a Japan-based pharmaceutical company involved in the development of innovative sleeping pills and oral therapies for sleep-related conditions.

Major companies operating in the sleeping pills market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited, Aurobindo Pharma Ltd. , Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Mallinckrodt Pharmaceuticals plc, Idorsia Pharmaceuticals Ltd, Procter & Gamble Health Limited (P&G Health), Allegiant Health

North America was the largest region in the sleeping pills market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the sleeping pills market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sleeping pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sleeping pills market consists of sales of over-the-counter antihistamines, melatonin supplements, and herbal or natural sleep remedies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sleeping Pills Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses sleeping pills market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sleeping pills ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sleeping pills market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Medication Type: Prescription Sleeping Pills; Over The Counter (OTC) Sleeping Pills
• 2) By Product Type: Benzodiazepines; Non Benzodiazepines
• 3) By Sleep Disorder: Insomnia; Sleep Disorder; Restless Leg Syndrome Narcolepsy; Sleepwalking
• 4) By Consumer Demographics: Age Groups; Gender; Health Conditions
• 5) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospitals And Clinics; Health And Wellness Stores
• Subsegments:
• 1) By Prescription Sleeping Pills: Benzodiazepines; Non-Benzodiazepines; Antidepressants; Antihistamines; Melatonin Receptor Agonists; Orexin Receptor Antagonists
• 2) By Over The Counter (OTC): Diphenhydramine; Doxylamine; Melatonin Supplements; Valerian Root
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi S.A.; Abbott Laboratories; GSK plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Eisai Co Ltd.; Sun Pharmaceutical Industries Ltd.; Apotex Inc.; Cipla Limited; Aurobindo Pharma Ltd. ; Dr. Reddy's Laboratories Ltd.; Hikma Pharmaceuticals plc; Lupin Limited; Glenmark Pharmaceuticals Ltd.; Torrent Pharmaceuticals Ltd.; Perrigo Company plc; Mallinckrodt Pharmaceuticals plc; Idorsia Pharmaceuticals Ltd; Procter & Gamble Health Limited (P&G Health); Allegiant Health
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.